Highlights:
- Published ATTRACT data call into question validity of the Villalta scale
- Brave Dreams trial finds venoplasty “safe, but largely ineffective” for MS patients
- Johann C Ragg: Percutaneous valvuloplasty
- Nicholas Osborne: VQI Varicose Vein Registry
- Profile: Armando Mansilha
[pdfviewer width=”100%” height=”940px” beta=”true”]https://venousnews.com/wp-content/uploads/sites/19/2018/02/Venous-News-4-low-res-EU.pdf[/pdfviewer]
Dear Sir, In my opinion -Why ATTRACT clinical trials on IR m/m of Acute DVT Failed?
Reasons are-
a)Pharmaco-mechanical thrombolysis done with devices mostly used in treating Arterial thrombosis.
Since clot burden in ‘Venous disease’ is MORE.These devices failed to generate successful thrombolysis results.
More “Dedicated Angiojet Zelante Thrombectomy Device” should have been used.
b)Risk-benefits ratio of lysing ilio-femoral DVT Vs Femoral DVT Not taken into account.
c) Response of thrombus at different Anatomical levels not considered.
d) Surprisingly CANCER patients and Malignancy induced DVT Excluded from trial.
e) Inj.Reteplase(rt-PA) should have been used instead of Inj.Alteplase. Also Inj.Urokinase with Heparin combination works well. .
Let me know other Consultant Drs opinion on this burning & hot debated issue of ATTARACT Trial?
With best wishes & Rgds!
-Dr.Mangesh P.TARTE,MD,FVIR,PGDMLS
Consultant Phlebologist & Interventional Radiologist
Ahmednagar,Maharashtra state,INDIA